Belzutifan

(Welireg®)

Belzutifan

Drug updated on 11/29/2023

Dosage FormTablet (oral; 40 mg)
Drug ClassHypoxia-inducible factor inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

Product Monograph / Prescribing Information

Document TitleYearSource
Welireg (belzutifan) Prescribing Information.2022Merck & Co. Inc., Rahway, NJ

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Belzutifan for renal cell carcinoma in von Hippel–Lindau disease.
61Subjects
F: 48%
M: 52%
2021New England Journal of Medicine

Sex Distribution:

F:48%
M:52%
61Subjects

Year:

2021

Source:New England Journal of Medicine

Clinical Practice Guidelines

Document TitleYearSource
von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance.2022European Journal of Medical Genetics